[PDF] Top 20 Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives

... differences between the HCV-2 and -3 patients: indeed, when splitting SVR rates according to genotype, HCV-2 patients achieved 93% SVR, compared to only 56% in HCV-3 ...of treatment failure only in HCV-3, ... See full document

... protective treatment options will be available in the near ...The current standard for care, according to the Ameri- can Association for the Study of Liver Diseases and Eur- opean guidelines, is a ... See full document

... improves treatment efficacy and decreases the incidence of AEs, yet a number of issues ...limited treatment options for patients with chronic kidney disease (CKD), patients coinfected with HCV and ... See full document

... some evidence to support the use of SOF/VEL/ VOX to achieve SVR without additional safety ...of Hepatitis B Virus (HBV) reactivation in patients co- infected with HCV/HBV while taking ...HBV ... See full document

... so-called chronic daily headache, it is not easy for migraine that worsens progressively until it becomes daily or almost daily to find a precise and universally recognized place within the current interna- ... See full document

... of evidence has prompted the FDA to approve GLE/PIB for the treatment of adult patients with chronic HCV GT 1 – 6 infection without cirrhosis (8 weeks of treatment) or with compensated ... See full document

... HCV treatment, enhancing the cure bar to above 90% [7–9]. Sofosbuvir is mainly eliminated through renal pathway, and its use in patients with stage 4 and 5 CKD, defined according to KDIGO guidelines (GFR ... See full document

... critical. Hepatitis C virus seems to be one of the major health problems in Egypt which have the highest prevalence in the ...is between 1% and ...14.7%. Hepatitis C virus affects most ... See full document

... Abstract: Chronic hepatitis C virus infection (HCV) has a negative impact on the long-term survival of recipients of kidney ...the current standard of care in hemodialyzed patients with HCV ... See full document

... Abstract: Chronic hepatitis C treatment has continued to evolve, and interferon-free, oral treatment with direct-acting antiviral agents is the current standard of ...new ... See full document

... Current study included 80 patients having HCV confirmed by PCR. Mean age was 49.2 ± 15.31 years, with age ranging from 17 to 83 years. Family history of positive contacts included first degree relatives including ... See full document

... Among treatment-experienced patients with advanced fibrosis or cirrhosis, previous relapsers are likely to respond very well to telaprevir- or boceprevir-based treatment, although advanced liver disease had ... See full document

... Hepatitis C virus (HCV) is a member of Flaviviridae family and one of the major causes of liver ...of chronic HCV treatment having 38-43% sustained virological response ...HCV treatment ... See full document

... genotypes. Sofosbuvir has highly potent antiviral activity across all genotypes in association with pegylated interferon and ribavirin (PR), thus allowing shortened treatment ...or ... See full document

... benchmark treatment no longer efficient, whereas treatments oly- sio + sovaldi and sofosbuvir + peginterferon + ribavirin both achieve higher QALYs but with increased costs compared to benchmark ...and ... See full document

... The λmax of Sofosbuvir was determined by analyzing the drug solution in double beam ultraviolet spectrophotometer. Accurately weighed 10 mg of drug was dissolved in 10 ml of 7.2 pH buffer solution in 10 ml of ... See full document

... “short treatment duration and acceptable adverse events” ...with chronic HCV with either a combination of simeprevir and sofosbuvir only, or RBV plus the two ...IFN-free treatment seems to be ... See full document

... GS-331007 were also done at day seven in the first 10 patients enrolled, as well as with sparse sampling throughout treat- ment, and were found to be comparable to prior SOF studies with adults. The primary efficacy ... See full document

... Nanorobotics is emerging as a leading field in the research of robotics at the nanometer scale. Nanorobotics comprises of robots that are at the nanometer scale in size and also larger robots that are able to manipulate ... See full document

... Hepatitis C virus (HCV) is a major causative agent of chronic hepatitis, hepatic cirrhosis and hepatocellular carcinoma ...by chronic HCV infection and being referred for liver ... See full document